Analyzing Resistance to Design Selective Chemical Inhibitors for AAA Proteins.
AAA Proteins
/ genetics
Adenosine Triphosphatases
/ metabolism
Amitrole
/ chemistry
Biochemical Phenomena
Catalytic Domain
Crystallography, X-Ray
/ methods
Drug Design
Humans
Microtubules
/ metabolism
Models, Molecular
Point Mutation
/ genetics
Protein Engineering
/ methods
Spastin
/ antagonists & inhibitors
Triazoles
/ chemistry
Tubulin
/ chemistry
AAA protein
JNJ-7706621
X-ray crystallography
chemical inhibitor
drug design
mutagenesis
resistance
spastazoline
spastin
Journal
Cell chemical biology
ISSN: 2451-9448
Titre abrégé: Cell Chem Biol
Pays: United States
ID NLM: 101676030
Informations de publication
Date de publication:
19 09 2019
19 09 2019
Historique:
received:
02
04
2019
revised:
15
05
2019
accepted:
31
05
2019
pubmed:
2
7
2019
medline:
28
7
2020
entrez:
2
7
2019
Statut:
ppublish
Résumé
Drug-like inhibitors are often designed by mimicking cofactor or substrate interactions with enzymes. However, as active sites are comprised of conserved residues, it is difficult to identify the critical interactions needed to design selective inhibitors. We are developing an approach, named RADD (resistance analysis during design), which involves engineering point mutations in the target to generate active alleles and testing compounds against them. Mutations that alter compound potency identify residues that make key interactions with the inhibitor and predict target-binding poses. Here, we apply this approach to analyze how diaminotriazole-based inhibitors bind spastin, a microtubule-severing AAA (ATPase associated with diverse cellular activities) protein. The distinct binding poses predicted for two similar inhibitors were confirmed by a series of X-ray structures. Importantly, our approach not only reveals how selective inhibition of the target can be achieved but also identifies resistance-conferring mutations at the early stages of the design process.
Identifiants
pubmed: 31257183
pii: S2451-9456(19)30182-5
doi: 10.1016/j.chembiol.2019.06.001
pmc: PMC6754270
mid: NIHMS1532976
pii:
doi:
Substances chimiques
JNJ-7706621
0
Triazoles
0
Tubulin
0
Adenosine Triphosphatases
EC 3.6.1.-
AAA Proteins
EC 3.6.4.-
Spastin
EC 3.6.4.3
SPAST protein, human
EC 5.6.1.1
Amitrole
ZF80H5GXUF
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1263-1273.e5Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM115327
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM130234
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR027037
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR022321
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM098579
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007739
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Science. 2001 Aug 3;293(5531):876-80
pubmed: 11423618
Science. 2004 Jul 16;305(5682):399-401
pubmed: 15256671
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Med Chem. 2005 Jun 30;48(13):4208-11
pubmed: 15974571
Methods Biochem Anal. 2005;46:1-265
pubmed: 16350889
Structure. 2007 Oct;15(10):1258-71
pubmed: 17937915
Nature. 2007 Dec 13;450(7172):1001-9
pubmed: 18075579
Nature. 2008 Jan 17;451(7176):363-7
pubmed: 18202664
Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7
pubmed: 18602262
Drug Discov Today. 2008 Oct;13(19-20):831-41
pubmed: 18617015
Traffic. 2009 Jan;10(1):42-56
pubmed: 19000169
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Bioorg Med Chem Lett. 2010 Dec 15;20(24):7454-7
pubmed: 21106455
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4834-9
pubmed: 21383145
Biochim Biophys Acta. 2012 Jan;1823(1):2-14
pubmed: 21839118
Acta Crystallogr D Biol Crystallogr. 2011 Nov;67(Pt 11):915-9
pubmed: 22101817
Nat Chem Biol. 2012 Feb 12;8(3):235-7
pubmed: 22327403
Nature. 2012 Mar 18;484(7392):125-9
pubmed: 22425997
Annu Rev Biochem. 2012;81:587-613
pubmed: 22482904
Trends Pharmacol Sci. 2012 May;33(5):268-72
pubmed: 22503476
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67
pubmed: 22505256
Nat Chem Biol. 2013 Sep;9(9):548-56
pubmed: 23892893
EMBO J. 2013 Nov 13;32(22):2920-37
pubmed: 24065130
N Engl J Med. 2014 Jun 12;370(24):2352-4
pubmed: 24869597
Trends Pharmacol Sci. 2015 Feb;36(2):78-95
pubmed: 25543280
Nature. 2015 Jun 11;522(7555):231-5
pubmed: 26040712
Cancer Cell. 2015 Nov 9;28(5):653-665
pubmed: 26555175
Science. 2016 Feb 19;351(6275):871-5
pubmed: 26822609
PLoS Biol. 2016 May 24;14(5):e1002464
pubmed: 27219477
Cell. 2016 Oct 6;167(2):512-524.e14
pubmed: 27667686
Top Antivir Med. 2017 Dec/Jan;24(4):132-133
pubmed: 28208121
Science. 2017 Feb 24;355(6327):
pubmed: 28209641
ACS Med Chem Lett. 2017 May 17;8(6):618-621
pubmed: 28626521
Science. 2017 Nov 3;358(6363):
pubmed: 29097521
Mol Cell. 2018 Jan 18;69(2):182-194
pubmed: 29153394
Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1576-1580
pubmed: 29271116
Nat Rev Drug Discov. 2018 May;17(5):353-377
pubmed: 29545548
Annu Rev Cell Dev Biol. 2018 Oct 6;34:85-109
pubmed: 30095293
J Med Chem. 2018 Dec 27;61(24):11183-11198
pubmed: 30457858
Cell Chem Biol. 2019 Jan 17;26(1):9-15
pubmed: 30482678
Mol Pharmacol. 2019 Mar;95(3):286-293
pubmed: 30591537
Nat Chem Biol. 2019 May;15(5):444-452
pubmed: 30778202
J Am Chem Soc. 2019 Apr 10;141(14):5602-5606
pubmed: 30875216